Novacyt's IFRS loss for 2021 was €9.728 million, compared to a profit of €132.423 million in the previous year. Revenue decreased 2.9 times to €95.78 million from €277.204 million a year earlier.

Novacyt S.A. IFRS net profit for 6 months. 2020 was €40.195 million, against a loss of €1.208 million in the previous year. Revenue increased 10 times to €72.374 million, compared to €7.223 million a year earlier.

Novacyt is developing a biogenic PCR test to better identify COVID-19, as well as a respiratory panel that can distinguish it from influenza A, B and respiratory syncytial viruses. The company is going to launch these products on the market in September 2020. In addition, the company carries out its own assessment of the effectiveness of the partner develope...

Novacyt, together with Queen Mary University of London, began clinical trials using an innovative stationary testing system. The aim of the study is to find out whether daily COVID-19 testing reduces the frequency of infection, morbidity and mortality among high-risk populations. The study will involve 2000 people in 50 nursing homes in London.